¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"acquired hemolytic anemia"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
¿µ¹® aplastic anemia ÇÑ±Û Àç»ýºÒ·®ºóÇ÷
¼³¸í   
  Àç»ýºÒ·®¼º ºóÇ÷À̶õ °ñ¼öÀÇ ÀÌ»óÀ¸·Î »ý±â´Â ºóÇ÷ÀÌ´Ù. °ñ¼ö¶õ »À¼Ó¿¡ Á¸ÀçÇϴ °ÍÀ¸·Î Ç÷±¸¸¦ »ý¼ºÇϴ ¼¼Æ÷µé°ú ¹Ì¼º¼÷ÇÑ Ç÷±¸µé·Î ÀÌ·ç¾îÁ® ÀÖ´Ù. À̰͵éÀÌ ¿©·¯ °¡Áö ¿øÀο¡ ÀÇÇØ¼­ ÆÄ±«µÇ¾úÀ» ¶§ »ý±â´Â ºóÇ÷À» Àç»ýºÒ·®ºóÇ÷À̶ó°í ÇÑ´Ù. ±×·¯¹Ç·Î ÀûÇ÷±¸¸¸ÀÇ °¨¼Ò°¡ ¾Æ´Ï¶ó ¸ðµç Ç÷±¸ ¼¼Æ÷ÀÇ °¨¼Ò¸¦ º¼ ¼ö ÀÖ´Ù. Ä¡·á·Î´Â Ç÷±¸ »ý¼ºÀ» ÀÚ±ØÇϴ ȣ¸£¸óÀ» Åõ¿©Çϴ °ÍÀÌ ÀÖÁö¸¸ À̰ÍÀ¸·Î´Â ÆÄ±«µÈ Ç÷±¸¸¦ »ý¼ºÇϴ ¼¼Æ÷ÀÇ Àç»ýÀÌ ÀϾÁö ¸øÇϹǷΠ¿ÏÀüÇÑ Ä¡·á¶ó°í´Â º¼ ¼ö°¡ ¾ø´Ù. ¿ÏÀüÇÑ Ä¡·á·Î´Â ³²ÀÇ °ñ¼ö¸¦ Ã¤ÃëÇØ¼­ À̰Ϳ¡¼­ºÎÅÍ Ç÷±¸¸¦ »ý¼ºÇϴ ¼¼Æ÷¸¦ ºÐ¸®, È¯ÀÚ¿¡°Ô À̽ÄÇϴ °ñ¼öÀ̽ÄÀÌ ÀÖ´Ù.
¿µ¹® iron deficiency anemia ÇÑ±Û Ã¶°áÇ̺óÇ÷
¼³¸í   
  ÀûÇ÷±¸ÀÇ ±â´ÉÀº »ê¼Ò¸¦ ¿î¹ÝÇϴµ¥ ÀÖ´Ù. ÀûÇ÷±¸ ¼Ó¿¡ »ê¼Ò¿Í °áÇÕÀ» ÇÏ¿© »ê¼Ò¸¦ ¿î¹ÝÇϴ Ç÷»ö¼Ò¶ó´Â ¹°ÁúÀÌ ÀÖ´Ù. Ã¶Àº ÀÌ Ç÷»ö¼ÒÀÇ Áß¿äÇÑ ºÎºÐÀ» ÀÌ·ç´Â °ÍÀ¸·Î Ã¶ÀÌ ¾øÀ¸¸é Ç÷»ö¼Ò°¡ ¸¸µé¾îÁú ¼ö°¡ ¾ø´Ù. Ç÷»ö¼Ò°¡ ¾øÀ¸¸é ¿ª½Ã ÀûÇ÷±¸µµ ¸¸µé¾îÁöÁö ¾ÊÀ¸¹Ç·Î Ã¼³»¿¡ Ã¶ÀÌ ºÎÁ·Çϸ頺óÇ÷ÀÌ »ý±ä´Ù. À̠ö°áÇ̼º ºóÇ÷Àº ºóÇ÷ÀÇ ¿øÀΠÁß¿¡¼­ °¡Àå ÈçÇÑ °ÍÀÌ´Ù(¾à 25%¸¦ Â÷ÁöÇÑ´Ù). Ã¶ÀúÀå·®ÀÇ ÀúÇÏ-°áÇÌ, Ç÷ûö³óµµÀÇ ÀúÇÏ, Æ®¶õ½ºÆä¸°·® »ó½Â, Æ®¶õ½ºÆä¸°Æ÷È­µµÀÇ ÀúÇÏ, Ç÷»ö¼Ò³óµµ ¶Ç´Â Ç츶ÅäÅ©¸®Æ®ÀÇ ÀúÇÏ, Àú»ö¼Ò¼º´ëÀûÇ÷±¸¸¦ Æ¯Â¡À¸·Î Çϴ ºóÇ÷·Î¼­, »ýü ³»¿¡¼­ Ã¶ÀÌ Àå±â¿¡ °ÉÃÄ °áÇ̵Ǹ砱נ¶§¹®¿¡ Ç÷»ö¼Ò »ý»ê °¨¼Ò¿¡ ÀÇÇØ ÀϾ´Ù. Ã¢ÀÚ¿¡¼­ÀǠöÈí¼ö·® ºÎÁ·, Ã¶ÀÇ ¼ö¿ä Áõ´ë(À¯¾Æ±â, »çÃá±â, ÀÓ½Å), Ã¶¼Ò½Ç°úÀ×(ÃâÇ÷)¿¡ ÀÇÇØ ÀϾ¸ç, Æ¯È÷ »çÃá±â¿¡¼­ Æó°æ±â±îÁöÀÇ ¿©¼º¿¡°Ô ¸¹´Ù. Áõ»óÀ¸·Î¼­´Â ¾ó±¼Ã¢¹é, ÇǷΰ¨, ÇǺÎâ¹é, ¼ÕÅé º¯È­(½ºÇ¬ ¸ð¾ç) µîÀ» ³ªÅ¸³½´Ù. ±¸°­ ¿µ¿ª¿¡¼­´Â ÇôÀÇ Á¢ÃËÅë, ¹ßÀû, °ÇÁ¶°¨, »ïÅ´°ï¶õÀ» ¼ö¹ÝÇϸé Ç÷¯¸Ó-ºó½¼(Plummer-Vinson)ÁõÈıºÀ̶ó°í ÇÑ´Ù. Ç÷¾× ¼Ò°ßÀº Ç÷ûöÀº ÀúÇÏÇϸç, Ã¶°áÇÕ´É·ÂÀÇ »ó½Â, Àú»ö¼Ò¼º ÀÛÀºÀûÇ÷±¸¼ºÀ» ³ªÅ¸³½´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acquired immunity
    ÈÄõ¸é¿ª
  • acquired immunodeficiency syndrome
    ÈÄõ¸é¿ª°áÇÌÁõÈıº, ¿¡ÀÌÁî
  • acquired megacolon
    ÈÄõ°Å´ëÀß·ÏâÀÚ, ÈÄõ°Å´ë°áÀå
  • acquired perforating dermatosis
    ÈÄõõ°øÇǺκ´
  • acquired progressive lymphangioma
    ÈÄõÁøÇาÇÁ°üÁ¾
  • acquired resistance
    ȹµæÀúÇ×
  • acquired tolerance
    ȹµæ³»¼º
  • hospital acquired infection
    º´¿ø°¨¿°, ¿ø³»°¨¿°
  • acute hemolytic transfusion reaction
    ±Þ¼º¿ëÇ÷¼º¼öÇ÷¹ÝÀÀ
  • delayed hemolytic transfusion reaction
    Áö¿¬¿ëÇ÷¼º¼öÇ÷¹ÝÀÀ
  • hemolytic
    1. ¿ëÇ÷- 2. ¿ëÇ÷Á¦
  • hemolytic activity
    ¿ëÇ÷´É
  • hemolytic antibody
    ¿ëÇ÷Ç×ü
  • hemolytic chain
    ¿ëÇ÷»ç½½
  • hemolytic crisis
    ¿ëÇ÷À§±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acquired cystic kidney disease
    ÈÄõ³¶¼ºÄáÆÏº´
  • acquired immune deficiency
    ÈÄõ¸é¿ª°áÇÌ
  • acquired immune deficiency syndrome
    ÈÄõ¸é¿ª°áÇÌÁõÈıº, ¿¡ÀÌÁî
  • acquired immunodeficiency syndrome
    ÈÄõ¸é¿ª°áÇÌÁõÈıº, ¿¡ÀÌÁî
  • acquired perforating dermatosis
    ÈÄõõ°øÇǺκ´
  • acquired progressive lymphangioma
    ÈÄõÁøÇาÇÁ°üÁ¾
  • hospital acquired infection
    ¿ø³»°¨¿°, º´¿ø°¨¿°
  • acute hemolytic transfusion reaction
    ±Þ¼º¿ëÇ÷¼öÇ÷¹ÝÀÀ
  • hemolytic activity
    ¿ëÇ÷´É
  • hemolytic antibody
    ¿ëÇ÷Ç×ü
  • hemolytic plaque assay
    ¿ëÇ÷ÆÇÃøÁ¤¹ý, ¿ëÇ÷ÇöóÅ©ÃøÁ¤¹ý
  • hemolytic chain
    ¿ëÇ÷»ç½½
  • hemolytic crisis
    ¿ëÇ÷À§±â
  • hemolytic plaque-forming cell
    ¿ëÇ÷ÆÇÇü¼º¼¼Æ÷, ¿ëÇ÷ÇöóÅ©Çü¼º¼¼Æ÷
  • delayed hemolytic transfusion reaction
    Áö¿¬¿ëÇ÷¼öÇ÷ºÎÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acquired B
    ȹµæ B Çü
  • acquired angioedema
    ÈÄõ¼º(ý­ô¸àõ) ¸Æ°üºÎÁ¾(ØæÎ·Ý©ðþ)
  • acquired blindness
    ÈÄõ¸Í.
  • acquired character
    ÈÄõÇüÁú(¡­û¡òõ).
  • acquired color vision defect
    ÈÄõ»ö°¢ÀÌ»ó
  • acquired cystic disease of the kidney
    ÈÄõ¼º ½Å³¶Æ÷Áúȯ
  • acquired deafness
    ÈÄõ(¼º) ³­Ã» ³ó
  • acquired digital fibrokeratoma
    ÈÄõ¼º ¼Õ¹ß°¡¶ô ¼¶À¯ °¢È­Á¾
  • acquired disease
    ÈÄõ¼º Áúº´(¡­òðÜ»).
  • acquired heart disease =AHD
    ÈÄõ¼º ½ÉÁúȯ(¡­ãýòðü´).
  • acquired hyperoxaluria
    ÈÄõ¼º °í¼ö»ê´¢Áõ
  • acquired ichthyosis
    ÈÄõ¼º(ý­ô¸àõ)¾î¸°¼±(åà×÷àÈ)
  • acquired immune deficiency
    ÈÄõ¼º ¸é¿ª°áÇÌ
  • acquired immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª°áÇÌ ÁõÈıº
  • acquired immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª°áÇÌÁõÈıº(ý­ô¸àõ Øóæ¹ÌÀù¹ñøý¦ÏØ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • extrinsic hemolytic anemia
    ¿ÜÀμº¿ëÇ÷¼º ºóÇ÷
  • familial hemolytic anemia
    °¡Á·¼º ¿ëÇ÷¼º ºóÇ÷.
  • heat induced hemolytic anemia
    ¿­À¯¹ß¼º ¿ëÇ÷¼º ºóÇ÷
  • hemolytic anemia
    ¿ëÇ÷¼º ºóÇ÷
  • hemolytic anemia
    ¿ëÇ÷¼º ºóÇ÷.
  • hemolytic anemia
    ¿ëÇ÷¼º ºóÇ÷(éÁúìàõÞ¸úì)
  • hemolytic anemia
    ¿ëÇ÷¼ººóÇ÷
  • hereditary nonspherocytic hemolytic anemia
    À¯Àü¼ººñ±¸»óÀûÇ÷±¸¿ëÇ÷¼ººóÇ÷
  • hereditary nonspherocytic hemolytic anemia
    À¯Àü¼º ºñ±¸Çü ÀûÇ÷±¸¼º ¿ëÇ÷¼º ºóÇ÷.
  • idiopathic autoimmune hemolytic anemia
    Ư¹ß(¼º) ÀÚ°¡¸é¿ª ¿ëÇ÷¼º ºóÇ÷.
  • immune cause (hemolytic anemia)
    ¸é¿ª¿øÀÎ(¿ëÇ÷¼ººóÇ÷)
  • immune hemolytic anemia
    ¸é¿ª¿ëÇ÷¼º ºóÇ÷
  • immune incompatibility (hemolytic anemia)
    ¸é¿ªºÎÀûÇÕ(¿ëÇ÷¼ººóÇ÷)
  • intravascular hemolytic anemia
    Ç÷°ü³»¿ëÇ÷¼º ºóÇ÷
  • intrinsic hemolytic anemia
    ³»Àμº ¿ëÇ÷¼º ºóÇ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • pernicious anemia
    ¾Ç¼º ºóÇ÷(äÂàõÞ¸úì)
  • sickle cell anemia
    ³´¼¼Æ÷(á¬øà)ºóÇ÷(Þ¸úì)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AIHD acquired immune hemolytic disease
IAHD idiopathic acquired hemolytic disorder
SAIDS sexually acquired immunodeficiency syndrome; simian acquired immune deficiency syndrome
AHA Autoimmune Hemolytic Anemia
AIHA Auto-Immune Hemolytic Anemia
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
GABHS Group A beta hemolytic streptococcal
GBS Group B beta hemolytic streptococci
GBS Group B beta--hemolytic streptococcus
HTR Hemolytic transfusion reactions
TTP-HUS Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • hemolytic-uremic syndrome
    ¿ëÇ÷¼º ¿äµ¶ ÁõÈıº
  • minimum hemolytic dose
    ÃÖ¼Ò ¿ëÇ÷·®
  • acquired
    ȹµæµÈ, ÈÄõ¼º, ÈÄõ¼ºÀÇ, ȹµæ¼ºÀÇ
    1. ¾î¶² °ÍÀ¸·ÎºÎÅÍ ¾òÀº, »õ·Ó°Å³ª ºÎ°¡ÀûÀΠƯ¼º. 2. ½Ã°£À» °¡Áö°í ´Þ¼ºÇÏ´Â. 3. ž ¶§ºÎÅÍ °¡Áö°í ÀÖ´Â °ÍÀÌ ¾Æ´Ï°í ž ÈÄ »ýüÀÇ ¿ÜºÎ¿¡¼­ ±âÀÎÇÏ´Â ¿µÇâ¿¡ ÀÇÇÏ¿© ÀϾ´Â.
  • acquired anomaly
    ÈÄõ¼º ±âÇü
  • acquired centric jaw relation
    ÈÄõ¼º Áß½ÉÀ§ ¾Ç°£ °ü°è, ½À°ü¼º Áß½ÉÀ§ ¾Ç°£ °ü°è
  • acquired centric relation
    ÈÄõ¼º Áß½ÉÀ§, ½À°ü¼º Áß½ÉÀ§
  • acquired clotting defect
    ÈÄõ¼º ÀÀ°í °á¼Õ
  • acquired cystic disease
    ÈÄõ¼º ³¶¼º Áúȯ
  • acquired deafness
    ÈÄõ ³­Ã» ³ó
  • acquired digital fibrokeratoma
    ÈÄõ¼º ¼Õ¹ß°¡¶ô ¼¶À¯ °¢È­Á¾
  • acquired disorder
    ÈÄõ¼º Àå¾Ö
    ¼±ÃµÀûÀÌ ¾Æ´Ï°í Ãâ»ý ÈÄ Á¤»óÀûÀÎ ¹ßÀ°¿¡ ÀÌ»óÀÌ »ý±â°Å³ª, º¯È­°¡ ¿À°Å³ª, Àå¾Ö°¡ ÀϾ °Í.
  • acquired eccentric relation
    ÈÄõ¼º Æí½ÉÀ§ ¾Ç°£°ü°è
    »ó¾Ç¿¡ ´ëÇÑ ÇϾÇÀÇ ¾î¶² Æí½ÉÀûÀÎ À§Ä¡ °ü°è·Î Ä¡¾ÆÀÇ Á¢ÃËÀ» °¡Á®¿Ã ¼ö ÀÖ´Ù.
  • acquired heart disease
    ÈÄõ¼º ½É Áúȯ
    »ýÈÄ¿¡ ¾ò¾îÁø ½ÉÀå Áúȯ.
  • acquired hyperoxaluria
    ÈÄõ¼º °í¼ö»ê´¢Áõ
  • acquired ichthyosis
    ÈÄõ¼º ¾î¸°¼±
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
acquired hypogammaglobulinaemia Heterogeneous group of immunodeficiency syndromes characterised by hypogammaglobulinaemia of most isotypes, variable B-cell defects, and the presence of recurrent bacterial infections.
(12 Dec 1998)
acquired ichthyosis A thickening and scaling of the skin associated with some malignant diseases (e.g., Hodgkin's disease, lymphosarcoma), leprosy, and severe nutritional deficiencies.
(05 Mar 2000)
acquired immunity <immunology> A form of cellular defense which identifies certain foreign substances (antigens) as harmful to the body. For this reason, the body can acquire resistance to a particular foreign agent.
These foreign agents are then attacked by sensitised T lymphocytes (cellular immunity). White blood cells, plasma cells, B lymphocytes and other specialised immune system cells act in concert with T lymphocytes to produce antibodies (humoral immunity) that attach to the antigen directing T-cells to attack.
Antibodies also stimulate the release of special chemical mediators in the blood (for example complement, interferon) that further enhance antigen destruction.
(13 Nov 1997)
acquired immunodeficiency disease Acquired immunodeficiency disease: Disease caused by infection with the human immunodeficiency virus (HIV).
(12 Dec 1998)
Acquired Immunodeficiency Syndrome <immunology, syndrome> An epidemic disease caused by an infection by human immunodeficiency virus (HIV-1, HIV-2), a retrovirus that causes immune system failure and debilitation and is often accompanied by infections such as tuberculosis. AIDS is spread through direct contact with bodily fluids.
Acronym: AIDS
(10 May 1997)
acquired leukoderma <dermatology> This disorder is characterised by regions of otherwise normal skin of nonpigmented white patches of varied sizes, often symmetrically distributed and usually bordered by hyperpigmented areas. Hair in the affected areas is usually, but not always, white.
(27 Sep 1997)
acquired leukopathia <dermatology> This disorder is characterised by regions of otherwise normal skin of nonpigmented white patches of varied sizes, often symmetrically distributed and usually bordered by hyperpigmented areas. Hair in the affected areas is usually, but not always, white.
(27 Sep 1997)
acquired megacolon Megacolon occurring on the basis of an acquired disease; occurs in inflammatory bowel disease (toxic megacolon) and Chagas' disease (South American trypanosomiasis).
(05 Mar 2000)
acquired methemoglobinaemia Methemoglobinaemia caused by various chemical agents, such as nitrites.
Synonym: enterogenous methemoglobinaemia, secondary methemoglobinaemia.
(05 Mar 2000)
acquired mutation A change in a gene or chromosome that occurs in a single cell after the conception of the individual. That change is then passed along to all cells descended from that cell. Acquired mutations are involved in the development of cancer.
(12 Dec 1998)
acquired nevus A melanocytic nevus that is not visible at birth, but appears in childhood or adult life.
(05 Mar 2000)
acquired pellicle A thin film (about 1 um), derived mainly from salivary glycoproteins, which forms over the surface of a cleansed tooth crown when it is exposed to the saliva.
Synonym: acquired cuticle, acquired enamel cuticle, brown pellicle, posteruption cuticle.
(05 Mar 2000)
acquired platelet function defect <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines).
Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation.
(29 Dec 1997)
acquired reflex A reflex that is gradually developed by training and association through the frequent repetition of a definite stimulus.
See: conditioning.
Synonym: acquired reflex, behaviour reflex, trained reflex.
(05 Mar 2000)
acquired sensitivity 1. <immunology> A state of hypersensitivity induced by exposure to a particular antigen (allergen) resulting in harmful immunologic reactions on subsequent exposures, the term is usually used to refer to hypersensitivity to an environmental antigen (atopic allergy or contact dermatitis) or to drug allergy.
The original meaning, now obsolete, included all states of altered immunologic reactivity, immunity as well as hypersensitivity. Gell and Coombs used the term allergic reaction to mean any harmful immunologic reaction causing tissue injury.
2. <study> The medical specialty dealing with diagnosis and treatment of allergic disorders.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á